Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0E1HF
|
||||
| Former ID |
DIB004540
|
||||
| Drug Name |
FFC-14A
|
||||
| Synonyms |
KP 1019; KP-692; HInd(RuInd2CI4), University of Vienna; KP-1019 (anhydrous); Ruthenium(III) complex, Faustus Forschung
|
||||
| Indication | Solid tumours [ICD9: 140-199, 210-229; ICD10:C00-D48] | Phase 1 | [1] | ||
| Company |
Faustus Forschungs Cie Translational Cancer Research GmbH
|
||||
| Structure |
|
Download2D MOL |
|||
| Canonical SMILES |
n1[nH]c2c(c1)cccc2.n1[nH]c2c(c1)cccc2.n1[nH]c2c(c1)cccc<br />2.[Ru-](Cl)(Cl)(Cl)Cl
|
||||
| Target and Pathway | |||||
| Target(s) | Human DNA | Target Info | Binder | [2] | |
| References | |||||
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004610) | ||||
| REF 2 | The heterocyclic ruthenium(III) complex KP1019 (FFC14A) causes DNA damage and oxidative stress in colorectal tumor cells. Cancer Lett. 2005 Aug 26;226(2):115-21. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.